OncoMed’s demcizumab fails to meet primary endpoint in pancreatic cancer trial

This article was originally published here

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in previously untreated metastatic pancreatic cancer patients.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply